Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pracinostat - MEI Pharma

Drug Profile

Pracinostat - MEI Pharma

Alternative Names: SB-939

Latest Information Update: 10 Jan 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator S*BIO
  • Developer Helsinn; MEI Pharma; S*BIO; University of Texas M. D. Anderson Cancer Center
  • Class Acrylamides; Antineoplastics; Hydroxamic acids; Small molecules
  • Mechanism of Action Histone deacetylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Acute myeloid leukaemia
  • Phase II Myelodysplastic syndromes; Myelofibrosis
  • Phase I Cancer

Most Recent Events

  • 21 Dec 2018 Pracinostat licensed to Berlin Chemie worldwide (excluding USA, Canada, Japan and South America) for commercialisation
  • 03 Dec 2018 Interim adverse events and efficacy data from a phase II trial in Myelodysplastic Syndromes released by MEI Pharma
  • 01 Dec 2018 Interim adverse events data from a phase-II trial in Myelodysplastic syndromes presented at the 60th Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem-2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top